Chen, Ziheng http://orcid.org/0000-0003-1918-106X
Ho, I-Lin
Soeung, Melinda http://orcid.org/0000-0002-6902-898X
Yen, Er-Yen http://orcid.org/0000-0003-2918-5419
Liu, Jintan http://orcid.org/0000-0001-6609-9777
Yan, Liang
Rose, Johnathon L.
Srinivasan, Sanjana
Jiang, Shan
Edward Chang, Q.
Feng, Ningping
Gay, Jason P.
Wang, Qi http://orcid.org/0000-0003-0858-9393
Wang, Jing http://orcid.org/0000-0002-5398-0802
Lorenzi, Philip L. http://orcid.org/0000-0003-0385-7774
Veillon, Lucas J.
Wei, Bo
Weinstein, John N. http://orcid.org/0000-0001-9401-6908
Deem, Angela K.
Gao, Sisi
Genovese, Giannicola
Viale, Andrea
Yao, Wantong
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Marszalek, Joseph R. http://orcid.org/0000-0003-2320-3209
Draetta, Giulio F. http://orcid.org/0000-0001-5225-9610
Ying, Haoqiang http://orcid.org/0000-0003-0616-2310
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA221707, P50CA221707, P01CA117969, R01CA248160, R01CA248160, S10OD012304-01, S10OD012304-01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
V Foundation for Cancer Research (P01CA117969)
UT | University of Texas MD Anderson Cancer Center (19-65-YAO)
Cancer Prevention and Research Institute of Texas (19-65-YAO)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Sewell Family Distinguished University Chair in Genomic Medicine
Article History
Received: 11 March 2022
Accepted: 4 April 2023
First Online: 17 April 2023
Competing interests
: C.A.L. has received consulting fees from Astellas Pharmaceuticals and Odyssey Therapeutics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in cancer, and targeting the GOT1-pathway as a therapeutic approach. The remaining authors declare no competing interests.